4 results about "Cmv infections" patented technology

Modified platelet-derived growth factor receptor alpha (PDGFRα) polypeptides are described. The modified polypeptides include at least one amino acid substitution that allows the polypeptide to retain the capacity to bind a cytomegalovirus (CMV) trimer comprised of glycoprotein H (gH), gL and gO, but leads to reduced binding to one or more platelet-derived growth factor (PDGF) ligands. Use of the modified PDGFRα polypeptides for inhibiting CMV replication and / or spread, or treating a CMV infection, is also described.

This invention discloses the application of the NbTuA gene in *Nicotiana benthamiana* in regulating plant resistance to turnip mosaic virus (CMV) and a method for cultivating transgenic plants. The NbTuA gene sequence is shown in SEQ ID NO:1. This invention involves cloning the NbTuA gene from *Nicotiana benthamiana* and constructing a vector fused with a YFP tag. Genetic transformation is then performed using Agrobacterium-mediated T-DNA transformation to construct transgenic plants of *Nicotiana benthamiana*. The *Nicotiana benthamiana* NbTuA transgenic plants obtained by this invention can significantly inhibit CMV infection.

Provided herein are immunogenic polypeptides, compositions, and methods related to the development of CMV-specific prophylactic and / or therapeutic immunotherapies based on cytotoxic T cell (CTL)-recognized T cell epitopes (e.g., CMV epitopes), and can be used to prevent and / or treat CMV infection, reactivation, and / or disease (e.g., CMV-associated end-organ disease), especially in solid organ transplant recipients.

Provided herein are compositions and methods for treating a virus-related disease or disorder. In certain instances, the compositions and methods are useful for treating CMV infection.